<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130687</url>
  </required_header>
  <id_info>
    <org_study_id>121253</org_study_id>
    <nct_id>NCT02130687</nct_id>
  </id_info>
  <brief_title>Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure</brief_title>
  <official_title>Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4)&#xD;
      inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE)&#xD;
      inhibition but not angiotensin receptor blockade or calcium channel blockade. The&#xD;
      investigators further hypothesize that this effect is mediated by substance P.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes&#xD;
      (T2DM) is growing rapidly. The majority of patients with T2DM are also taking ACE inhibitors&#xD;
      or angiotensin receptor blockers (ARBs) in order to reduce cardiovascular and renal morbidity&#xD;
      and mortality. DPP4 and ACE inhibitors share the common vasoactive substrate substance P.&#xD;
      Substance P acts as a vasodilator but also activates the sympathetic nervous system.&#xD;
      Understanding the interactive effects of DPP4 and ACE inhibitors on blood pressure and&#xD;
      neurohumoral activation has important implications for the millions of patients with T2DM who&#xD;
      take these drugs concurrently.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Arterial Blood Pressure</measure>
    <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
    <description>The primary analyses will focus on mean arterial blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
    <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine (NE) Concentrations</measure>
    <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
    <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Frequency Variability of Blood Pressure Activity</measure>
    <time_frame>for 5 minutes on the 7th day of each intervention</time_frame>
    <description>Low frequency variability of blood pressure will be measured using spectral analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>for 9 hours for the first 18 subjects per group and 4.5 hours for subsequent subjects, on the 7th day of each intervention</time_frame>
    <description>measure of effectiveness of DPP4 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>for 9 hours for the first 18 subjects per group and 4.5 hours for subsequent subjects, on the 7th day of each intervention</time_frame>
    <description>Measure of insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dipeptidyl Peptidase IV (DPP4) Activity</measure>
    <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
    <description>Measure of DPP4 inhibitor administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiotensin Converting Enzyme (ACE)</measure>
    <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
    <description>Measure of ACE inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone, Angiotensin II, and Plasma Renin Activity (PRA)</measure>
    <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
    <description>renin-angiotensin system measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
    <description>measurement before and after ingestion of a mixed meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
    <description>measurement before and after ingestion of a mixed meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurohormonal and Vasoactive Peptide Measurements</measure>
    <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
    <description>Measurement of Neuropeptide Y (NPY), Peptide YY (PYY), Glucagon-like peptide-1 (GLP-1), Free Fatty Acids (FFA), and Norepinephrine (NE) before and after ingestion of a mixed meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr Urinary Testing for Catecholamines, Sodium, Potassium, Creatinine</measure>
    <time_frame>24hrs prior to each study day</time_frame>
    <description>Subjects will collect 24hr urine sample and bring with to the study day for analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Microcrystalline cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mixed Meal Test (MMT)</intervention_name>
    <description>The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age 18 to 80 years old&#xD;
&#xD;
        For female subjects the following conditions must be met:&#xD;
&#xD;
        Postmenopausal status for at least 1 year, or Status-post surgical sterilization, or If of&#xD;
        childbearing potential, utilization of barrier methods of birth control and willingness to&#xD;
        undergo urine β-HCG testing prior to drug treatment and on every study day&#xD;
&#xD;
        T2DM, as defined by 1 or more of the following at the time of screening visit:&#xD;
&#xD;
          -  Hgb A1C ≥6.5%, or&#xD;
&#xD;
          -  Fasting plasma glucose ≥126mg/dL, or&#xD;
&#xD;
          -  2-hour plasma glucose ≥200 mg/dL following 75gr oral glucose load&#xD;
&#xD;
        Hypertension, as defined by:&#xD;
&#xD;
          -  Seated SBP ≥130 mm Hg on three occasions documented in medical record, or&#xD;
&#xD;
          -  Seated DBP ≥80 mm Hg on three occasions documented in medical record, or&#xD;
&#xD;
          -  Treatment with antihypertensive medications for a minimum of 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Poorly controlled T2DM, defined as Hgb A1C&gt;8.7%&#xD;
&#xD;
          -  Use of anti-diabetic medications other than metformin for at least 12 months prior to&#xD;
             initiation of the study&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Subjects who have participated in a weight-reduction program during the last 6 months&#xD;
             and whose weight has increased or decreased more than 5 kg over the preceding 6 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Treatment with drugs primarily metabolized through CYP3A4 (e.g. cisapride, pimozide)&#xD;
&#xD;
          -  Clinically significant gastrointestinal impairment that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
          -  Cardiovascular disease such as myocardial infarction within 6 months prior to&#xD;
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart&#xD;
             failure (LV hypertrophy and diastolic dysfunction acceptable), deep vein thrombosis,&#xD;
             pulmonary embolism, second- or third-degree AV block, mitral valve stenosis, or&#xD;
             hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino&#xD;
             transaminase [ALT] &gt;3 x upper limit of normal range)&#xD;
&#xD;
          -  Impaired renal function (eGFR&lt; 50mL/min/1.73m2 as determined by the MDRD equation)&#xD;
&#xD;
          -  History or presence of immunological or hematological disorders.&#xD;
&#xD;
          -  History of pancreatitis or know pancreatic lesion&#xD;
&#xD;
          -  History of angioedema while taking an ACE inhibitor&#xD;
&#xD;
          -  Hematocrit &lt;35%&#xD;
&#xD;
          -  Treatment with anticoagulants&#xD;
&#xD;
          -  Diagnosis of asthma requiring use of inhaled β-2 agonist more than 1 time per week&#xD;
&#xD;
          -  Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult&#xD;
&#xD;
          -  Treatment with systemic glucocorticoids within the last 6 months&#xD;
&#xD;
          -  Treatment with lithium salts&#xD;
&#xD;
          -  Treatment with any investigational drug in the 1 month preceding the study&#xD;
&#xD;
          -  Mental conditions rendering the subject unable to understand the nature, scope, or&#xD;
             possible consequences of the study&#xD;
&#xD;
          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>May 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2014</study_first_posted>
  <results_first_submitted>April 17, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2021</results_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown, MD</investigator_full_name>
    <investigator_title>Hugh Jackson Morgan Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Angiotensin Converting Enzyme Inhibitors</keyword>
  <keyword>Dipeptidyl Peptidase IV Inhibitors</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Aprepitant</keyword>
  <keyword>Ramipril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02130687/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were enrolled if they met inclusion and exclusion criteria. 174 were consented to enroll 106. In other words, 68 of 174 consented were excluded because they did not meet inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine</title>
          <description>Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
        <group group_id="P2">
          <title>Ramipril</title>
          <description>Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
        <group group_id="P3">
          <title>Valsartan</title>
          <description>Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Drug 1 Only</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Drug 1 Only Between Periods 1 and 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Drug 1 Only Between Periods 2 and 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are provided for all participants who were randomized whether or not they received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine</title>
          <description>Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
        <group group_id="B2">
          <title>Ramipril</title>
          <description>Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
        <group group_id="B3">
          <title>Valsartan</title>
          <description>Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
Placebo: Subjects will receive two capsules of placebo to preserve the blinding of the study.&#xD;
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.&#xD;
Sitagliptin: Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.&#xD;
Aprepitant: Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.&#xD;
Mixed Meal Test (MMT): The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="10.9"/>
                    <measurement group_id="B2" value="52.9" spread="9.9"/>
                    <measurement group_id="B3" value="57.9" spread="10.4"/>
                    <measurement group_id="B4" value="56.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Arterial Blood Pressure</title>
        <description>The primary analyses will focus on mean arterial blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
        <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Placebo/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine Plus Sitagliptin/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine Plus Sitagliptin/Aprepitant</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Ramipril Plus Placebo/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for one week for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Ramipril Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule.</description>
          </group>
          <group group_id="O6">
            <title>Ramipril Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O7">
            <title>Valsartan Plus Placebo/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O8">
            <title>Valsartan Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Valsartan Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Blood Pressure</title>
          <description>The primary analyses will focus on mean arterial blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.42" spread="7.53"/>
                    <measurement group_id="O2" value="93.41" spread="8.75"/>
                    <measurement group_id="O3" value="91.54" spread="7.80"/>
                    <measurement group_id="O4" value="90.21" spread="12.46"/>
                    <measurement group_id="O5" value="89.88" spread="9.67"/>
                    <measurement group_id="O6" value="86.95" spread="10.16"/>
                    <measurement group_id="O7" value="94.54" spread="9.96"/>
                    <measurement group_id="O8" value="93.71" spread="10.75"/>
                    <measurement group_id="O9" value="93.98" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
        <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Placebo/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine Plus Sitagliptin/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine Plus Sitagliptin/Aprepitant</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Ramipril Plus Placebo/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for one week for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Ramipril Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule.</description>
          </group>
          <group group_id="O6">
            <title>Ramipril Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O7">
            <title>Valsartan Plus Placebo/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O8">
            <title>Valsartan Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Valsartan Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.59" spread="9.75"/>
                    <measurement group_id="O2" value="70.43" spread="9.79"/>
                    <measurement group_id="O3" value="69.41" spread="9.84"/>
                    <measurement group_id="O4" value="66.58" spread="7.71"/>
                    <measurement group_id="O5" value="66.30" spread="8.16"/>
                    <measurement group_id="O6" value="66.15" spread="8.06"/>
                    <measurement group_id="O7" value="66.19" spread="9.19"/>
                    <measurement group_id="O8" value="65.86" spread="8.46"/>
                    <measurement group_id="O9" value="65.10" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Norepinephrine (NE) Concentrations</title>
        <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
        <time_frame>4.5 hours on the 7th day of each intervention (placebo, sitagliptin, or sitagliptin+aprepitant)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Placebo/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine Plus Sitagliptin/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine Plus Sitagliptin/Aprepitant</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Ramipril Plus Placebo/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for one week for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Ramipril Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule.</description>
          </group>
          <group group_id="O6">
            <title>Ramipril Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O7">
            <title>Valsartan Plus Placebo/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O8">
            <title>Valsartan Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Valsartan Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Norepinephrine (NE) Concentrations</title>
          <description>The primary analyses will focus on blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="28"/>
                <count group_id="O9" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741.65" spread="660.82"/>
                    <measurement group_id="O2" value="730.88" spread="613.69"/>
                    <measurement group_id="O3" value="610.65" spread="587.19"/>
                    <measurement group_id="O4" value="470.69" spread="474.88"/>
                    <measurement group_id="O5" value="627.55" spread="593.92"/>
                    <measurement group_id="O6" value="649.39" spread="624.67"/>
                    <measurement group_id="O7" value="874.22" spread="863.75"/>
                    <measurement group_id="O8" value="986.31" spread="1114.67"/>
                    <measurement group_id="O9" value="1013.54" spread="1073.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Frequency Variability of Blood Pressure Activity</title>
        <description>Low frequency variability of blood pressure will be measured using spectral analysis.</description>
        <time_frame>for 5 minutes on the 7th day of each intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose</title>
        <description>measure of effectiveness of DPP4 inhibitor</description>
        <time_frame>for 9 hours for the first 18 subjects per group and 4.5 hours for subsequent subjects, on the 7th day of each intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin</title>
        <description>Measure of insulin resistance.</description>
        <time_frame>for 9 hours for the first 18 subjects per group and 4.5 hours for subsequent subjects, on the 7th day of each intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dipeptidyl Peptidase IV (DPP4) Activity</title>
        <description>Measure of DPP4 inhibitor administration.</description>
        <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Plus Placebo/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine Plus Sitagliptin/Placebo</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine Plus Sitagliptin/Aprepitant</title>
            <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Ramipril Plus Placebo/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for one week for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Ramipril Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule.</description>
          </group>
          <group group_id="O6">
            <title>Ramipril Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
          <group group_id="O7">
            <title>Valsartan Plus Placebo/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
          </group>
          <group group_id="O8">
            <title>Valsartan Plus Sitagliptin/Placebo</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and a placebo capsule for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Valsartan Plus Sitagliptin/Aprepitant</title>
            <description>Participants in this group received valsartan 320mg/d for 15 weeks. During this intervention period they also received sitagliptin 100mg/day and aprepitant 125mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Dipeptidyl Peptidase IV (DPP4) Activity</title>
          <description>Measure of DPP4 inhibitor administration.</description>
          <units>nmol/mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.27" spread="6.80"/>
                    <measurement group_id="O2" value="7.34" spread="2.98"/>
                    <measurement group_id="O3" value="6.96" spread="4.33"/>
                    <measurement group_id="O4" value="20.61" spread="6.24"/>
                    <measurement group_id="O5" value="8.78" spread="6.5"/>
                    <measurement group_id="O6" value="7.71" spread="3.4"/>
                    <measurement group_id="O7" value="19.4" spread="7.14"/>
                    <measurement group_id="O8" value="7.83" spread="4.07"/>
                    <measurement group_id="O9" value="6.70" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiotensin Converting Enzyme (ACE)</title>
        <description>Measure of ACE inhibition</description>
        <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aldosterone, Angiotensin II, and Plasma Renin Activity (PRA)</title>
        <description>renin-angiotensin system measurements</description>
        <time_frame>for 4.5 hours on the 7th day of each intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>measurement before and after ingestion of a mixed meal</description>
        <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>measurement before and after ingestion of a mixed meal</description>
        <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurohormonal and Vasoactive Peptide Measurements</title>
        <description>Measurement of Neuropeptide Y (NPY), Peptide YY (PYY), Glucagon-like peptide-1 (GLP-1), Free Fatty Acids (FFA), and Norepinephrine (NE) before and after ingestion of a mixed meal</description>
        <time_frame>during mixed meal test, for the first 18 subjects per group, on the 7th day of each intervention, 4 hours total (time points 5 to 9 hours on study day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24hr Urinary Testing for Catecholamines, Sodium, Potassium, Creatinine</title>
        <description>Subjects will collect 24hr urine sample and bring with to the study day for analysis</description>
        <time_frame>24hrs prior to each study day</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected through study completion or for approximately 15 weeks.</time_frame>
      <desc>Information for adverse events are provided for each anti-hypertensive group. Most events occurred during periods before or between crossover treatment periods and these are listed as such.</desc>
      <group_list>
        <group group_id="E1">
          <title>Washout Prior to Amlodipine</title>
          <description>Subjects in this arm received calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. Subjects underwent washout prior to starting amlodipine.</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine Alone</title>
          <description>Subjects in this arm received calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects received three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions were: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
During the first four weeks and between crossover therapies, participants received amlodipine alone.</description>
        </group>
        <group group_id="E3">
          <title>Amlodipine Plus Sitagliptin/Placebo</title>
          <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Amlodipine Plus Placebo/Placebo</title>
          <description>Participants received amlodipine 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100 mg/day and a placebo capsule for 7 days.</description>
        </group>
        <group group_id="E5">
          <title>Amlodipine Plus Sitagliptin/Aprepitant</title>
          <description>Participants received amlodipine 10mg/day for 15 weeks. During this intervention period they also received sitagliptin 100 mg/day and aprepitant 125 mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
        </group>
        <group group_id="E6">
          <title>Washout Prior to Ramipril</title>
          <description>Subjects received ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. Subjects underwent washout prior to starting ramipril.</description>
        </group>
        <group group_id="E7">
          <title>Ramipril Alone</title>
          <description>Subjects received ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks.&#xD;
After 4 weeks of treatment, subjects received three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions were: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
During the first four weeks and between crossover therapies, participants received ramipril alone.</description>
        </group>
        <group group_id="E8">
          <title>Ramipril Plus Placebo/Placebo</title>
          <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
        </group>
        <group group_id="E9">
          <title>Ramipril Plus Sitagliptin/Placebo</title>
          <description>Participants in this group received ramipril 10mg/d for 15 weeks. During this intervention period they also received sitagliptin 100 mg/day and a placebo capsule for 7 days.</description>
        </group>
        <group group_id="E10">
          <title>Ramipril Plus Sitagliptin/Aprepitant</title>
          <description>Participants in this group received ramipril 10mg/d for 15 days. During this intervention period they also received sitagliptin 100 mg/day and aprepitant 125 mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
        </group>
        <group group_id="E11">
          <title>Washout Prior to Valsartan</title>
          <description>Subjects received ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. Subjects underwent washout prior to starting valsartan.</description>
        </group>
        <group group_id="E12">
          <title>Valsartan Alone</title>
          <description>Subjects received ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects received three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.&#xD;
During the first four weeks and between crossover therapies, participants received valsartan alone.</description>
        </group>
        <group group_id="E13">
          <title>Valsartan Plus Placebo/Placebo</title>
          <description>Participants in this group received valsartan 320 mg/d for 15 weeks. During this intervention period they also received two placebo capsules for 7 days.</description>
        </group>
        <group group_id="E14">
          <title>Valsartan Plus Sitagliptin/Placebo</title>
          <description>Participants in this group received valsartan 320 mg/d for 15 weeks. During this intervention period they also received sitagliptin 100 mg/day and a placebo capsule for 7 days.</description>
        </group>
        <group group_id="E15">
          <title>Valsartan Plus Sitagliptin/Aprepitant</title>
          <description>Participants in this group received valsartan 320 mg/d for 15 weeks. During this intervention period they also received sitagliptin 100 mg/day and aprepitant 125 mg/d for one day followed by 80 mg/d for a total of 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>unstable angina</sub_title>
                <description>stenting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>elevated blood pressure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>orthostasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy J. Brown, M.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>16153644022</phone>
      <email>nancy.j.brown@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

